Since Nrf2 activation inhibits adipocyte differentiation, the benefits of an Nrf2 activator administration on HFD-induced obesity seems to be through the direct inhibition of adipocyte differentiation [140,141]. The gene discussed is NFE2L2; the disease is obesity disorder.